Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) studyAbbasi, A., Corpeleijn, E., Meijer, E., Postmus, D., Gansevoort, R. T., Gans, R. O. B., Struck, J., Hillege, H. L., Stolk, R. P., Navis, G. & Bakker, S. J. L., Jul-2012, In : Diabetologia. 55, 7, p. 1963-1970 8 p.
Research output: Contribution to journal › Article › Academic › peer-review
- Life Course Epidemiology (LCE)
- Reproductive Origins of Adult Health and Disease (ROAHD)
- Cardiovascular Centre (CVC)
- Groningen Institute for Organ Transplantation (GIOT)
- Lifestyle Medicine (LM)
- Groningen Kidney Center (GKC)
- Vascular Ageing Programme (VAP)
- Methods in Medicines evaluation & Outcomes research (M2O)
Vasopressin plays a role in osmoregulation, glucose homeostasis and inflammation. Therefore, plasma copeptin, the stable C-terminal portion of the precursor of vasopressin, has strong potential as a biomarker for the cardiometabolic syndrome and diabetes. Previous results were contradictory, which may be explained by differences between men and women in responsiveness of the vasopressin system. The aim of this study was to evaluate the usefulness of copeptin for prediction of future type 2 diabetes in men and women separately.
From the Prevention of Renal and Vascular Endstage Disease (PREVEND) study, 4,063 women and 3,909 men without diabetes at baseline were included. A total of 208 women and 288 men developed diabetes during a median follow-up of 7.7 years.
In multivariable-adjusted models, we observed a stronger association of copeptin with risk of future diabetes in women (OR 1.49 [95% CI 1.24, 1.79]) than in men (OR 1.01 [95% CI 0.85, 1.19]) (p (interaction) <0.01). The addition of copeptin to the Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) clinical model improved the discriminative value (C-statistic,+0.007, p = 0.02) and reclassification (integrated discrimination improvement [IDI] = 0.004, p <0.01) in women. However, we observed no improvement in men. The additive value of copeptin in women was maintained when other independent predictors, such as glucose, high sensitivity C-reactive protein (hs-CRP) and 24 h urinary albumin excretion (UAE), were included in the model.
The association of plasma copeptin with the risk of developing diabetes was stronger in women than in men. Plasma copeptin alone, and along with existing biomarkers (glucose, hs-CRP and UAE), significantly improved the risk prediction for diabetes in women.
|Number of pages||8|
|Publication status||Published - Jul-2012|
- Copeptin, Prediction, Sex, Type 2 diabetes, Vasopressin, C-REACTIVE PROTEIN, URINARY ALBUMIN EXCRETION, METABOLIC SYNDROME, VASOPRESSIN RECEPTOR, INSULIN-RESISTANCE, RISK, MELLITUS, PREDICTION, GENDER, INDIVIDUALS
Gansevoort, R. (Creator), University of Groningen, 2017